Cost-effectiveness analysis of infant pneumococcal vaccination with PHiD-CV in Korea

Cost-effectiveness analysis of infant pneumococcal vaccination with PHiD-CV in Korea

Background: Streptococcus pneumoniae and non-typeable Haemophilus influenzae (NTHi) can cause invasive pneumococcal diseases (IPD), pneumonia, and acute otitis media (AOM). Both the 10-valent pneumococcal NTHi protein D conjugate vaccine (PHiD-CV) and the 13-valent pneumococcal conjugate vaccine (PC...

Full description

Bibliographic Details
Main Authors:	Xu-Hao Zhang, Oscar Leeuwenkamp, Kyu-Bin Oh, Young Eun Lee, Chul-Min Kim
Format:	Article
Language:	English
Published:	Taylor & Francis Group 2018-01-01
Series:	Human Vaccines & Immunotherapeutics
Subjects:	cost-effectiveness korea phid-cv pneumococcal vaccine
Online Access:	http://dx.doi.org/10.1080/21645515.2017.1362513

Similar Items

A 6-year safety surveillance of 10-valent pneumococcal non-typeable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV) in South Korea
by: Soon Min Lee, et al.
Published: (2018-12-01)

Effectiveness and impact of the 10-valent pneumococcal conjugate vaccine, PHiD-CV: review of clinical trials and post-marketing experience
by: Tomas Mrkvan, et al.
Published: (2018-09-01)

Overall effectiveness of pneumococcal conjugate vaccines: An economic analysis of PHiD-CV and PCV-13 in the immunization of infants in Italy
by: Paolo Castiglia, et al.
Published: (2017-10-01)

Exploring the evidence behind the comparable impact of the pneumococcal conjugate vaccines PHiD-CV and PCV13 on overall pneumococcal disease
by: Patricia Izurieta, et al.
Published: (2022-01-01)

Safety profile of the 10-valent pneumococcal non-typeable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV)
by: Sven Arne Silfverdal, et al.
Published: (2017-02-01)

A cost-effectiveness analysis of PHiD-CV compared to PCV13 in a national immunization program setting in Tunisia
by: Youness Lagoubi, et al.
Published: (2022-11-01)

Comment on: ‘Clinical and Economic Impact of a Potential Switch from 13-Valent to 10-Valent Pneumococcal Conjugate Infant Vaccination in Canada’, Wilson et al., 22 June 2018
by: Ashleigh McGirr, et al.
Published: (2018-11-01)

Safety, reactogenicity, and immunogenicity of a 12-valent pneumococcal non-typeable Haemophilus influenzae protein D-conjugate vaccine in healthy toddlers: results from a phase I, randomized trial
by: Michael Horn, et al.
Published: (2021-05-01)

Pneumonia hospitalizations of children aged <2 years in Poland before (2013–2016) and after (2017–2018) universal mass vaccination with 10-valent pneumococcal non-typeable Haemophilus influenzae protein D conjugate vaccine
by: Amit Bhavsar, et al.
Published: (2022-11-01)

Estimated public health impact of human rotavirus vaccine (HRV) and pneumococcal polysaccharide protein D-conjugate vaccine (PHiD-CV) on child morbidity and mortality in Gavi-supported countries
by: Alen Marijam, et al.
Published: (2022-12-01)

Trends in all-cause pneumonia and otitis media in children aged <2 years following pneumococcal conjugate vaccine introduction in Colombia
by: Gabriel Carrasquilla, et al.
Published: (2021-04-01)

Cost-effectiveness analysis of 13-valent pneumococcal conjugate vaccine versus 23-valent pneumococcal polysaccharide vaccine in an adult population in South Korea
by: Min-Joo Choi, et al.
Published: (2018-08-01)

Immunization with 10-valent pneumococcal non-typeable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV) according to different schedules in infants in South Africa: a phase III trial
by: Shabir A Madhi, et al.
Published: (2017-06-01)

Cost-effectiveness of a national immunization program with the 13-valent pneumococcal conjugate vaccine compared with the 10-valent pneumococcal conjugate vaccine in South Korea
by: Hye-Young Kim, et al.
Published: (2021-03-01)

Cost-effectiveness analysis of adult pneumococcal conjugate vaccines for pneumococcal disease in Japan
by: Shigeki Nakamura, et al.
Published: (2024-12-01)

Estimating the Cost-Effectiveness of Switching to Higher-Valency Pediatric Pneumococcal Conjugate Vaccines in the United Kingdom
by: Michele Wilson, et al.
Published: (2023-06-01)

The clinical, immunological and microbiological impact of the 10-valent pneumococcal-Protein D conjugate vaccine in children with recurrent protracted bacterial bronchitis, chronic suppurative lung disease and bronchiectasis: A multi-centre, double-blind, randomised controlled trial
by: Kerry-Ann F. O'Grady, et al.
Published: (2018-11-01)

Effects of prophylactic ibuprofen and paracetamol administration on the immunogenicity and reactogenicity of the 10-valent pneumococcal non-typeable Haemophilus influenzae protein D conjugated vaccine (PHiD-CV) co-administered with DTPa-combined vaccines in children: An open-label, randomized, controlled, non-inferiority trial
by: Oana Falup-Pecurariu, et al.
Published: (2017-03-01)

Review of vaccine effectiveness assumptions used in economic evaluations of infant pneumococcal conjugate vaccine
by: Matt Wasserman, et al.
Published: (2018-01-01)

Cost-effectiveness of 20-valent pneumococcal conjugate vaccine compared with 23-valent pneumococcal polysaccharide vaccine among adults in a Norwegian setting
by: Mikkelsen Malene B, et al.
Published: (2023-08-01)

A cost-effectiveness analysis of pneumococcal conjugate vaccines in infants and herd protection in older adults in Colombia
by: Jaime E. Ordóñez, et al.
Published: (2023-12-01)

An economic evaluation of pneumococcal conjugate vaccines, PCV20 versus PCV15, for the prevention of pneumococcal disease in the Swedish pediatric population
by: Ann-Charlotte Fridh, et al.
Published: (2024-12-01)

Estimating the Clinical and Economic Impact of Switching from the 13-Valent Pneumococcal Conjugate Vaccine (PCV13) to Higher-Valent Options in Greek Infants
by: Sophie Warren, et al.
Published: (2023-08-01)

Cost-effectiveness of use of 20-valent pneumococcal conjugate vaccine among adults in Germany
by: Felicitas Kühne, et al.
Published: (2023-12-01)

Cost-effectiveness of PCV20 to Prevent Pneumococcal Disease in the Pediatric Population: A German Societal Perspective Analysis
by: An Ta, et al.
Published: (2024-05-01)

Cost-effectiveness of the 13-valent pneumococcal conjugate vaccine in adults in Portugal versus “no vaccination” and versus vaccination with the 23-valent pneumococcal polysaccharide vaccine
by: Miguel Gouveia, et al.
Published: (2019-04-01)

Burden of Pneumococcal Disease in Young Children Due to Serotypes Contained in Different Pneumococcal Conjugate Vaccines in Eight Asian Countries and Territories
by: Liping Huang, et al.
Published: (2024-10-01)

Estimating the Clinical and Economic Impact of Switching from the 13-Valent Pneumococcal Conjugate Vaccine (PCV13) to the 10-Valent Pneumococcal Conjugate Vaccine (PCV10) in Italy
by: Filippo Ansaldi, et al.
Published: (2020-01-01)

Cost-utility analysis of a universal pneumococcal vaccination programme for older adults in Norway
by: Liv Solvår Nymark, et al.
Published: (2022-11-01)

Cost-effectiveness analysis of routine 13-valent pneumococcal conjugate vaccinations in Chinese infants
by: Hua Zhou, et al.
Published: (2018-06-01)

Cost-effectiveness analysis of PCV20 to prevent pneumococcal disease in the Canadian pediatric population
by: Derek Lytle, et al.
Published: (2023-08-01)

Cost-effectiveness of introducing a domestic pneumococcal conjugate vaccine (PCV7-TT) into the Cuban national immunization programme
by: Anai García Fariñas, et al.
Published: (2020-08-01)

Cost-Effectiveness Analysis of the Use of V116, a 21-Valent Pneumococcal Conjugate Vaccine, in Vaccine-Naïve Adults Aged ≥ 65 Years in the United States
by: Zinan Yi, et al.
Published: (2024-11-01)

The Cost-Effectiveness of 13-Valent Pneumococcal Conjugate Vaccine in Seven Chinese Cities
by: Yan Li, et al.
Published: (2021-11-01)

Effect of different schedules of ten-valent pneumococcal conjugate vaccine on pneumococcal carriage in Vietnamese infants: results from a randomised controlled trialResearch in context
by: Heidi Smith-Vaughan, et al.
Published: (2023-03-01)

Primary vaccination with the 10-valent pneumococcal non-typeable <it>Haemophilus influenzae </it>protein D conjugate vaccine (PHiD-CV) in infants in Mali and Nigeria: a randomized controlled trial
by: Dicko Alassane, et al.
Published: (2011-11-01)

Cost-Effectiveness of 20-Valent Pneumococcal Conjugate Vaccine in Argentinean Adults
by: Lucila Rey-Ares, et al.
Published: (2024-05-01)

Cost-utility of 20-valent pneumococcal conjugate vaccine compared to no vaccination and recommended alternative vaccines among Belgian adults
by: Sophie Marbaix, et al.
Published: (2023-10-01)

Health and economic burden associated with 15-valent pneumococcal conjugate vaccine serotypes in Korea and Hong Kong
by: Salini Mohanty, et al.
Published: (2022-11-01)

Intrafamilial Transmission of Pneumococcal Acute Spontaneous Peritonitis
by: Ioanna Papadatou, et al.
Published: (2023-05-01)